Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice

Adhikari et al. use the redox modulatory abilities of citrate functionalized Mn3O4 nanoparticles to ameliorate oxidative damage in murine disease model of chronic kidney disease (CKD). This nanomedicine works by protecting structural and functional integrity of mitochondria from oxidative injury, re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Aniruddha Adhikari, Susmita Mondal, Tanima Chatterjee, Monojit Das, Pritam Biswas, Ria Ghosh, Soumendra Darbar, Hussain Alessa, Jalal T. Althakafy, Ali Sayqal, Saleh A. Ahmed, Anjan Kumar Das, Maitree Bhattacharyya, Samir Kumar Pal
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/2e1b13424ead40f9aeabdec7b1deeefd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Adhikari et al. use the redox modulatory abilities of citrate functionalized Mn3O4 nanoparticles to ameliorate oxidative damage in murine disease model of chronic kidney disease (CKD). This nanomedicine works by protecting structural and functional integrity of mitochondria from oxidative injury, reducing intracellular ROS, downregulating pro-inflammatory cytokines and maintaining cellular redox homeostasis.